Migration and proliferation of retinal pigment epithelium on extracellular matrix ligands

Journal of Rehabilitation Research and Development

Volumn 43, Issue 6, 2006, Pages 713-722

  Wang, Hao ^a   Van Patten, Yancy ^a   Sugino, Ilene K ^a   Zarbin, Marco A ^a  

^a INSTITUTE OF OPHTHALMOLOGY AND VISUAL SCIENCE   (United States)

Author keywords

Age related macular degeneration; Aged retinal pigment epithelium; Bovine corneal endothelial cell extracellular matrix; Cell migration; Cell proliferation; Choroidal neovascularization; Extracellular matrix; Fetal retinal pigment epithelium

Indexed keywords

CELLS; LIVING SYSTEMS STUDIES; PIGMENTS; ROBUSTNESS (CONTROL SYSTEMS); VISION;

AGE RELATED MACULAR DEGENERATION; AGED RETINAL PIGMENT EPITHELIUM; BOVINE CORNEAL ENDOTHELIAL CELL EXTRACELLULAR MATRIX; CELL MIGRATION; CELL PROLIFERATION; CHOROIDAL NEOVASCULARIZATION; EXTRACELLULAR MATRIX; FETAL RETINAL PIGMENT EPITHELIUM; RETINAL PIGMENT EPITHELIUM (RPE);

TISSUE;

COLLAGEN TYPE 1; COLLAGEN TYPE 4; FIBRONECTIN; LAMININ; LIGAND;

ADULT; AGED; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CORNEA; COW; EXTRACELLULAR MATRIX; FETUS; HUMAN; HUMAN CELL; HUMAN TISSUE; MIGRATION; PIGMENT EPITHELIUM; PRIORITY JOURNAL;

AGE FACTORS; AGED; AGED, 80 AND OVER; CELL MOVEMENT; CELL PROLIFERATION; COLLAGEN TYPE I; COLLAGEN TYPE IV; EXTRACELLULAR MATRIX; FIBRONECTINS; HUMANS; LAMININ; MIDDLE AGED; PIGMENT EPITHELIUM OF EYE;

EID: 33846324737     PISSN: 07487711     EISSN: 07487711     Source Type: Journal    
DOI: 10.1682/JRRD.2005.06.0114     Document Type: Article

References (36)

1. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. 1992;99(6):933-43.
2. Sommer A, Tielsch JM, Katz J, Quigley HA, Gottsch JD, Javitt JC, Martone JF, Royall RM, Witt KA, Ezrine S. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med. 1991;325(20): 1412-17.
3. Klein R, Wang Q, Klein BE, Moss SE, Meuer SM. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci. 1995; 36(1):182-91.
4. Attebo K, Mitchell P, Smith W. Visual acuity and the causes of visual loss in Australia. The Blue Mountains Eye Study. Ophthalmology. 1996;103(3):357-64.
5. Rosenberg T, Klie F. Current trends in newly registered blindness in Denmark. Acta Ophthalmol Scand. 1996;74(4):395-98.
6. Vingerling JR, Dielemans I, Hofman A, Grobbee DE, Hijmering M, Kramer CF, De Jong PT. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology. 1995;102(2):205-10.
7. Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology. 1995;102(10):1450-60.
8. Klein R, Klein BE, Jensen SC, Meuer SM. The five-year incidence and progression of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology. 1997;104(1):7-21.
9. Freund KB, Yannuzzi LA, Sorenson JA. Age-related macular degeneration and choroidal neovascularization. Am J Ophthalmol. 1993;115(6):786-91.
10. Bressler NM, Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol. 2001;119(2):198-207.
11. Olsen TW, Feng X, Kasper T, Rath PP, Steuer ER. Exudative age-related macular degeneration: Fluorescein angiographic subtype prevalence. Invest Ophthalmol Vis Sci. 2001;42(4):S311.
12. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001; 131(5):541-60.
13. Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donati G, Hao Y, Ma C, Menchini U, Miller J, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Strong HA, Stur M, Su XY, Virgili G. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol. 2003;136(3):407-18.
14. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805-16.
15. Nasir MA, Sugino I, Zarbin MA. Decreased choriocapillaris perfusion following surgical excision of choroidal neovascular membranes in age-related macular degeneration. Br J Ophthalmol. 1997;81(6):481-89.
16. Grossniklaus HE, Hutchinson AK, Capone A Jr, Woolfson J, Lambert HM. Clinicopathologic features of surgically excised choroidal neovascular membranes. Ophthalmology. 1994;101(6):1099-1111.
17. Castellarin AA, Nasir MA, Sugino IK, Zarbin MA. Progressive presumed choriocapillaris atrophy after surgery for age-related macular degeneration. Retina. 1998;18(2):143-49.
18. Algvere PV, Berglin L, Gouras P, Sheng Y, Kopp ED. Transplantation of RPE in age-related macular degeneration: Observations in disciform lesions and dry RPE atrophy. Graefes Arch Clin Exp Ophthalmol. 1997;235(3):149-58.
19. Del Priore L, Kaplan HJ, Tezel TH, Berger AS. Retinal pigment epithelium transplantation for subfoveal neovascularization in exudative age-related macular degeneration: A clinical trial. Boca Roton (FL): The Macula Society; 1998.
20. Gouras P, Algvere V. Retinal cell transplantation in the macula: New techniques. Vision Res. 1996;36(24):4121-25.
21. Algvere PV, Berglin L, Gouras P, Sheng Y. Transplantation of fetal retinal pigment epithelium in age-related macular degeneration with subfoveal neovascularization. Graefes Arch Clin Exp Ophthalmol. 1994;232(12):707-16.
22. Algvere PV, Gouras P, Dafgard Kopp E. Long-term outcome of RPE allografts in non-immunosuppressed patients with AMD. Eur J Ophthalmol. 1999;9(3):217-30.
23. Sugino IK, Wang H, Zarbin MA. Age-related macular degeneration and retinal pigment epithelium wound healing. Mol Neurobiol. 2003;28(2):177-94.
24. Wang H, Ninomiya Y, Sugino IK, Zarbin MA. Retinal pigment epithelium wound healing on human Bruch's membrane explants. Invest Ophthalmol Vis Sci. 2003;44(5): 2199-2210.
25. Marshall GE, Konstas AG, Reid GG, Edwards JG, Lee WR. Type IV collagen and laminin in Bruch's membrane and basal linear deposit in the human macula. Br J Ophthalmol. 1992;76(10):607-14.
26. Das A, Frank RN, Zhang NL, Turczyn TJ. Ultrastructural localization of extracellular matrix components in human retinal vessels and Bruch's membrane. Arch Ophthalmol. 1990;108(3):421-29.
27. Ishida M, Lui GM, Yamani A, Sugino IK, Zarbin MA. Culture of human retinal pigment epithelial cells from peripheral scleral flap biopsies. Curr Eye Res. 1998;17(4):392-402.
28. Song MK, Lui GM. Propagation of fetal human RPE cells: Preservation of original culture morphology after serial passage. J Cell Physiol. 1990;143(1):196-203.
29. Tseng SC, Savion N, Gospodarowicz D, Stern R. Characterization of collagens synthesized by cultured bovine corneal endothelial cells. J Biol Chem. 1981;256(7):3361-65.
30. Gospodarowicz D, Gonzalez R, Fujii DK. Are factors originating from serum, plasma, or cultured cells involved in the growth-promoting effect of the extracellular matrix produced by cultured bovine corneal endothelial cells? J Cell Physiol. 1983;114(2):191-202.
31. Robinson J, Gospodarowicz D. Glycosaminoglycans synthesized by cultured bovine corneal endothelial cells. J Cell Physiol. 1983;117(3):368-76.
32. Nevo Z, Gonzalez R, Gospodarowicz D. Extracellular matrix (ECM) proteoglycans produced by cultured bovine corneal endothelial cells. Connect Tissue Res. 1984;13(1):45-57.
33. Sawada H, Furthmayr H, Konomi H, Nagai Y. Immunoelectronmicroscopic localization of extracellular matrix components produced by bovine corneal endothelial cells in vitro. Exp Cell Res. 1987;171(1):94-109.
34. Kay EP, Oh S. Modulation of type III collagen synthesis in bovine corneal endothelial cells. Invest Ophthalmol Vis Sci. 1988;29(2):200-207.
35. Richman GP, Tirrell DA, Asthagiri AR. Quantitatively distinct requirements for signaling-competent cell spreading on engineered versus natural adhesion ligands. J Control Release. 2005;101(1-3):3-12.
36. Langer R, Tirrell DA. Designing materials for biology and medicine. Nature. 2004;428(6982):487-92.